Cargando…

No evidence for substrate accumulation in Parkinson brains with GBA mutations

BACKGROUND: To establish whether Parkinson's disease (PD) brains previously described to have decreased glucocerebrosidase activity exhibit accumulation of the lysosomal enzyme's substrate, glucosylceramide, or other changes in lipid composition. METHODS: Lipidomic analyses and cholesterol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gegg, Matthew E., Sweet, Lindsay, Wang, Bing H., Shihabuddin, Lamya S., Sardi, Sergio Pablo, Schapira, Anthony H.V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2015
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4529481/ https://www.ncbi.nlm.nih.gov/pubmed/26096906 http://dx.doi.org/10.1002/mds.26278

Ejemplares similares

Ambroxol reverses tau and α-synuclein accumulation in a cholinergic N370S GBA1 mutation model
por: Yang, Shi Yu, et al.
Publicado: (2022)

Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models
por: Sanchez-Martinez, Alvaro, et al.
Publicado: (2016)

Glucosylceramide in cerebrospinal fluid of patients with GBA-associated and idiopathic Parkinson’s disease enrolled in PPMI
por: Huh, Young Eun, et al.
Publicado: (2021)

Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model
por: Viel, Catherine, et al.
Publicado: (2021)

Brain Microglial Activation Increased in Glucocerebrosidase (GBA) Mutation Carriers without Parkinson's disease
por: Mullin, Stephen, et al.
Publicado: (2020)

GBA Variants and Parkinson Disease: Mechanisms and Treatments
por: Smith, Laura, et al.
Publicado: (2022)

The GBA variant E326K is associated with alpha-synuclein aggregation and lipid droplet accumulation in human cell lines
por: Smith, Laura J, et al.
Publicado: (2022)

Intronic Haplotypes in the GBA Gene Do Not Predict Age at Diagnosis of Parkinson's Disease
por: Toffoli, Marco, et al.
Publicado: (2021)

Glucocerebrosidase activity, cathepsin D and monomeric α-synuclein interactions in a stem cell derived neuronal model of a PD associated GBA1 mutation
por: Yang, Shi-yu, et al.
Publicado: (2020)

Visual short-term memory deficits associated with GBA mutation and Parkinson’s disease
por: Zokaei, Nahid, et al.
Publicado: (2014)

Exploring the Genotype–Phenotype Correlation in GBA-Parkinson Disease: Clinical Aspects, Biomarkers, and Potential Modifiers
por: Menozzi, Elisa, et al.
Publicado: (2021)

GBA mutation promotes early mitochondrial dysfunction in 3D neurosphere models
por: Morén, Constanza, et al.
Publicado: (2019)

α-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism
por: Yun, Seung Pil, et al.
Publicado: (2018)

Endoplasmic reticulum and lysosomal Ca(2+) stores are remodelled in GBA1-linked Parkinson disease patient fibroblasts
por: Kilpatrick, Bethan S., et al.
Publicado: (2016)

Sphingolipid changes in Parkinson L444P GBA mutation fibroblasts promote α-synuclein aggregation
por: Galvagnion, Céline, et al.
Publicado: (2022)

A Human Neural Crest Stem Cell-Derived Dopaminergic Neuronal Model Recapitulates Biochemical Abnormalities in GBA1 Mutation Carriers
por: Yang, Shi-Yu, et al.
Publicado: (2017)

Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson’s Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial
por: Peterschmitt, M. Judith, et al.
Publicado: (2022)

Mitochondrial dysfunction associated with glucocerebrosidase deficiency
por: Gegg, Matthew E., et al.
Publicado: (2016)

Evaluation of the detection of GBA missense mutations and other variants using the Oxford Nanopore MinION
por: Leija‐Salazar, Melissa, et al.
Publicado: (2019)

DNA Methylation of α-Synuclein Intron 1 Is Significantly Decreased in the Frontal Cortex of Parkinson’s Individuals with GBA1 Mutations
por: Smith, Adam R., et al.
Publicado: (2023)

Mitochondrial Contribution to Parkinson's Disease Pathogenesis
por: Schapira, Anthony H. V., et al.
Publicado: (2011)

Evolution and clustering of prodromal parkinsonian features in GBA1 carriers
por: Mullin, Stephen, et al.
Publicado: (2019)

Genetic variations in GBA1 and LRRK2 genes: Biochemical and clinical consequences in Parkinson disease
por: Smith, Laura J., et al.
Publicado: (2022)

Murine Models of Lysosomal Storage Diseases Exhibit Differences in Brain Protein Aggregation and Neuroinflammation
por: Clarke, Jennifer, et al.
Publicado: (2021)

Sterol auto-oxidation adversely affects human motor neuron viability and is a neuropathological feature of amyotrophic lateral sclerosis
por: Dodge, James C., et al.
Publicado: (2021)

Recent developments in biomarkers in Parkinson disease
por: Schapira, Anthony H.V.
Publicado: (2013)

Mitochondrial dysfunction and mitophagy defect triggered by heterozygous GBA mutations
por: Li, Hongyu, et al.
Publicado: (2018)

Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease
por: Magalhaes, Joana, et al.
Publicado: (2016)

Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells
por: McNeill, Alisdair, et al.
Publicado: (2014)

Sex-Specific Microglial Responses to Glucocerebrosidase Inhibition: Relevance to GBA1-Linked Parkinson’s Disease
por: Brunialti, Electra, et al.
Publicado: (2023)

Biochemical consequences of glucocerebrosidase 1 mutations in Parkinson’s disease
por: Yoon, Jeong Hyun, et al.
Publicado: (2023)

Who is at Risk of Parkinson Disease? Refining the Preclinical Phase of GBA1 and LRRK2 Variant Carriers: a Clinical, Biochemical, and Imaging Approach
por: Menozzi, Elisa, et al.
Publicado: (2023)

Bioenergetic Consequences of PINK1 Mutations in Parkinson Disease
por: Abramov, Andrey Yurevich, et al.
Publicado: (2011)

Gene Therapy for Parkinson’s Disease Associated with GBA1 Mutations
por: Abeliovich, Asa, et al.
Publicado: (2021)

Glucosylceramide synthase inhibition reduces ganglioside GM3 accumulation, alleviates amyloid neuropathology, and stabilizes remote contextual memory in a mouse model of Alzheimer’s disease
por: Dodge, James C., et al.
Publicado: (2022)

The Consequences of GBA Deficiency in the Autophagy–Lysosome System in Parkinson’s Disease Associated with GBA
por: Pradas, Eddie, et al.
Publicado: (2023)

Comparative Transcriptome Analysis in Monocyte-Derived Macrophages of Asymptomatic GBA Mutation Carriers and Patients with GBA-Associated Parkinson’s Disease
por: Usenko, Tatiana, et al.
Publicado: (2021)

Elevation of gangliosides in four brain regions from Parkinson’s disease patients with a GBA mutation
por: Blumenreich, Shani, et al.
Publicado: (2022)

Comprehensive short and long read sequencing analysis for the Gaucher and Parkinson’s disease-associated GBA gene
por: Toffoli, Marco, et al.
Publicado: (2022)

Plasma Glucosylsphingosine in GBA1 Mutation Carriers with and without Parkinson's Disease
por: Surface, Matthew, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n7rdcmgo2kuovrtnqppnaf76tb